Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTITUDE-style kidney transplant immunosuppression switch study
2013-001798-26Phase 3Completed
- Sponsor
- CHU de Poitiers
- Start
- Aug 2013
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in kidney transplant comparing Switch to mycophenolic acid + everolimus at month 3 with Continue tacrolimus + everolimus (2 arms). Primary endpoint: Renal function at 12 months. Started Aug 2013; status: completed.
02
Drugs
mycophenolic acideverolimustacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2013-001798-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001798-26.